Press Releases

Date Title
07/11/17
Summary TogglePulse Biosciences to Host Quarterly Investor Conference Call on July 27, 2017
06/06/17
Summary TogglePulse Biosciences Announces Treatment of First Patient in Study to Evaluate the Safety and Efficacy of Novel Nano-Pulse Stimulation Technology for Seborrheic Keratosis Lesions
05/04/17
Summary TogglePulse Biosciences Quarterly Investor Conference Call
04/17/17
Summary TogglePulse Biosciences to Host Quarterly Investor Conference Call on May 4, 2017
03/14/17
Summary TogglePulse Biosciences Quartery Investor Conference Call
03/14/17
Summary TogglePulse Biosciences Submits 510(k) Application to FDA for PulseTx™ System
03/01/17
Summary TogglePulse Biosciences to Host Investor Conference Call on March 14, 2017
02/10/17
Summary TogglePulse Biosciences Announces Healthcare Executives and Entrepreneurs Robert Duggan and Dr. Maky Zanganeh Have Acquired a Combined Interest of 17.1% of the Company
11/14/16
Summary TogglePulse Biosciences Quarterly Nano-Pulse Stimulation (NPS) Update
11/14/16
Summary TogglePulse Biosciences Announces First Clinical Use of the Proprietary PulseTx Platform in a Pilot Study in Dermatology
11/11/16
Summary TogglePulse Biosciences Announces New Data That Reinforce Potential Immuno-Oncology Benefits of Nano-Pulse Stimulation Technology
11/02/16
Summary TogglePulse Biosciences to Host Third Quarter Investor Conference Call on November 14, 2016
10/18/16
Summary TogglePulse Biosciences to Present New Data at the Society for Immunotherapy in Cancer Annual Meeting
09/07/16
Summary TogglePulse Biosciences Provides Overview of Corporate Strategy and Updates on Clinical Development for Novel PulseTx Platform
08/30/16
Summary TogglePulse Biosciences Appoints Holly Hartman as Vice President of Business Development and Corporate Strategy